You are here: Industry Insights > gene therapy

News List

Spark Therapeutics’ Luxturna advisory committee vote sets gene therapy landmark fiercebiotech
October 16, 2017
After decades of research, a gene therapy to correct a specific genetic mutation is on the brink of being approved by the FDA.
Cancer, gene therapy biotechs raise $303M in IPO bonanza fiercebiotech
September 29, 2017
Three biotech companies focusing on cancer and eye diseases have collectively raised more than $300 million.
Gene therapy reverses symptoms, slows progression of MS in mice fiercebiotech
September 22, 2017
A gene therapy delivered to the liver delayed progression and reversed symptoms of early-stage multiple sclerosis in mice.
FDA approval brings first gene therapy to the United States worldpharmanews
August 31, 2017
The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases.
Krystal files for IPO to move gene therapies into clinic fiercebiotech
August 23, 2017
The Nasdaq listing will enable Krystal to get its treatment for dystrophic epidermolysis bullosa into human testing.
SCD Patients to Greet the First New Drug, the Gene Therapy to Hold Up Their Future en-cphi.cn
July 28, 2017
The Endari of Emmaus Life Sciences, Inc. was approved the marketing by FDA last week for symptom control of SCD (sickle cell disease) patients aged above 5. It is an oral L-glutamine and the first drug that can be used for pediatric patients with SCD.
Kolon Life Science wins license for gene therapy drug biospectrumasia
July 18, 2017
The new drug will be available for sale as early as September, with the company planning to conduct clinical tests in the United States at the end of the year.
Chesapeake IRB Acquires Institutional Biosafety Corp. contractpharma
June 07, 2017
Expands capability to provide review and oversight of research using recombinant or synthetic DNA molecules
Abeona Therapeutics receives FDA orphan designation for gene therapy europeanpharmaceuticalreview
May 31, 2017
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Abeona Therapeutics’s EB-101 gene therapy program for patients with dystrophic epidermolysis bullosa (DEB).
Sangamo and Pfizer to collaborate on Haemophilia A gene therapy europeanpharmaceuticalreview
May 18, 2017
Sangamo Therapeutics and Pfizer have announced an exclusive, global collaboration and license agreement for the development and commercialisation of gene therapy programs for Haemophilia A.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page